Myeloma

Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.

In the phase 3 CERVINO trial, etentamig improved response rates and progression-free survival compared with standard therapies in patients with relapsed/refractory multiple myeloma.

The FDA approved six cancer drugs in August 2026, including a landmark pancreatic cancer pill. Here's what each approval means for patients and side effects.

The FDA granted accelerated approval to Zenbexus with daratumumab and hyaluronidase-fihj and dexamethasone for previously treated multiple myeloma.

Mariska Hargitay discusses her father's myeloma, hope from research and the importance of community and caregivers for patients.

Mezigdomide, Kyprolis and dexamethasone cut progression risk by 52% in relapsed or refractory multiple myeloma.

Discover how a multiple myeloma survivor manages treatment and daily anxiety through Qigong, rituals and self-care.

Elrexfio improved progression-free survival in multiple myeloma, helping patients live longer without disease worsening in a phase 3 trial.

A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges of living with cancer.

FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after prior therapy, based on trial results showing longer disease control.

Learn how survivor Julie Cohen navigated high-risk multiple myeloma, failed treatments and the vital role of nurse navigators in chronic cancer care.

MGUS is a precursor condition that requires monitoring rather than aggressive intervention.

Daily practices help one writer find calm and stability while living with multiple myeloma.

ACS data show rising five-year survival and shifting cancer care toward survivorship, access to novel therapies and prevention as incidence climbs.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients live longer after cancer

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August.

Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options.